证券代码：603392 证券简称：万泰生物 公告编号：2024-063 北京万泰生物药业股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第一次临时股东大会 召开的日期时间：2024 年 11 月 11 日 14 点 00 分 召开地点：北京市昌平区科学园路 31 号公司会议室 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2024年11月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 11 日 至 2024 年 11 月 11 日 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-062 北京万泰生物药业股份有限公司 关于修订《公司章程》的公告 2023 年 8 月 29 日，公司首次披露了回购股份事项，具体内容详见公司在指 定信息披露媒体披露的《北京万泰生物药业股份有限公司关于以集中竞价交易方 式回购公司股份方案的公告》（公告编号：2023-062）。2024 年 9 月 12 日，公 司披露了《北京万泰生物药业股份有限公司关于股份回购实施结果暨股份变动的 公告》（公告编号：2024-058），股份回购实施期间，公司累计回购股份 3,084,225 股，回购的股份全部用于减少公司注册资本，公司已于 2024 年 9 月 12 日在中国 证券登记结算有限责任公司注销本次所回购的股份 3,084,225 股。 二、《公司章程》修订情况 鉴于公司股份回购实施完成后，公司股份总数和注册资本已经变动，根据《公 司法》《证券法》等相关法律规定和要求，《北京万泰生物药业股份有限公司章 程》中涉及公司股份总数和注册资本的条款需要相应进行修订。此外，结合公司 的日常治理需求，对董事长的权限进行调整。拟修订内容具体如下： | 原《公司章程》 ...

Group 1: Company Overview - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is listed under stock code 603392 and is known for its focus on biological pharmaceuticals [1] - The company held an investor relations activity on September 24, 2024, attended by various financial institutions including CITIC Securities and CICC [1] Group 2: Financial Management - The company plans to use up to 4.5 billion CNY of idle funds for cash management, investing in low-risk financial products [3] - Future share buyback or management increase plans will be considered based on actual needs and will comply with legal disclosure requirements [2] Group 3: Business Development - The company is enhancing its IVD (In Vitro Diagnostics) business by expanding product offerings and optimizing existing projects to meet clinical needs [3] - Future strategies include accelerating innovation in IVD products and expanding reagent menus, particularly for cancer and elderly disease markers [3] Group 4: Market Expansion - The company is focusing on domestic vaccine sales strategies and strengthening its sales team to penetrate deeper into the market [4] - Internationally, the company is pursuing product registration and collaborating with organizations like GAVI to explore new growth opportunities [4] Group 5: Collaboration and Partnerships - The termination of the collaboration agreement with GSK was a mutual decision, with the company not privy to GSK's internal requirements for clinical trials [4]

证券代码：603392 证券简称：万泰生物 公告编号：2024-059 北京万泰生物药业股份有限公司 关于参加医药生物行业上市公司 2024 年度 集中路演活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步展现公司经营发展情况，加强与广大投资者的互动交流，促进提升 公司质量和投资价值，北京万泰生物药业股份有限公司（以下简称"公司"）将 参加在深圳证券交易所上市大厅举办的"医药生物行业上市公司 2024 年度集中 路演"活动，现将相关事项公告如下： 二、投资者参与方式 1、本次活动投资者可在 2024 年 9 月 20 日(星期五)下午 14:00-17:00，登录 上海证券交易所上证路演中心（http://roadshow.sseinfo.com/），参与线上互动交 流。 2、为广泛听取投资者的意见和建议，提升交流的针对性，投资者可于 2024 年 9 月 19 日(星期四) 下午 16:00 前通过公司邮箱 wtzqb@ystwt.com 进行提问。 公司将在集中路演活动上对投资者普遍关注的问题进行回答。 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-058 北京万泰生物药业股份有限公司 关于股份回购实施结果暨股份变动的公告 （四）本次股份回购方案的实施对公司的影响 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | | | | | 2023/8/29，本次回购方案由时任公司董事长兼总经理邱 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 子欣先生提议。 | | | | | | | | 回购方案实施期限 | 年 2023 9 | 月 13 | 日~2024 | | 年 9 | 月 | 日 12 | | 预计回购金额 | 20,000 万元~40,000 | | | 万元 | | | | | 回购价格上限 | 98.00 元/股 | | | | | | | | 回购用途 | √减少注册资本 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 实际回购股数 | ...

重要内容提示： | 回购方案首次披露日 | 2023/8/29，本次回购方案由时任公司董事长兼总经理邱 | | | | --- | --- | --- | --- | | | 子欣先生提议。 | | | | 回购方案实施期限 | 2023 年 9 日~2024 年 月 | 月 13 | 9 12 日 | | 预计回购金额 | 万元 20,000 万元~40,000 | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 288.0385 | 万股 | | | 累计已回购股数占总 股本比例 | 0.2271% | | | | 累计已回购金额 | 18,612.53 | 万元 | | | 实际回购价格区间 | 45.55 元/股~74.48 元/股 | | | 一、 回购股份的基本情况 证券代码：603392 证券简称：万泰生物 公告编号：2024-057 北京万泰生物药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不 ...

Investment Rating - The investment rating for the company is "Buy" [12]. Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2024, with revenue at 1.366 billion yuan, down 67.19% year-on-year, and net profit at 260 million yuan, down 84.70% year-on-year [2][6]. - The company is advancing its product pipeline, including the acceptance of the application for the nine-valent HPV vaccine, which is expected to enhance its market position [5][6]. - The company has achieved market access for its bivalent HPV vaccine in 18 countries and is actively pursuing further international market development [6]. Financial Performance Summary - For 2024, the company expects revenues of 2.715 billion yuan, a decrease of 50.74% year-on-year, with a projected net profit of 558 million yuan, down 55.31% year-on-year [7]. - The company’s earnings per share (EPS) for 2024 is estimated at 0.44 yuan, with a compound annual growth rate (CAGR) of 46.61% from 2024 to 2026 [7]. - The company’s financial metrics indicate a significant drop in profitability, with EBITDA projected to be 1.199 billion yuan in 2024, down from 1.556 billion yuan in 2023 [4][7]. Market Position and Product Development - The company is the first domestic supplier of HPV vaccines, which positions it favorably in the market [7]. - The nine-valent HPV vaccine has completed key clinical trials and is on track for commercialization, with priority review status granted by the National Medical Products Administration [6][7]. - The company is also developing a 20-valent pneumonia conjugate vaccine and a new freeze-dried varicella vaccine, indicating a robust pipeline of products [6].

证券代码：603392 证券简称：万泰生物 公告编号：2024-056 北京万泰生物药业股份有限公司 关于公司九价 HPV 疫苗上市许可申请 获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司(以下简称"公司")全资子公司厦门 万泰沧海生物技术有限公司（以下简称"万泰沧海"）收到国家药品监督管理局 （以下简称"国家药监局"）药品审评中心下发的万泰沧海与厦门大学合作研发 的"重组人乳头瘤病毒 6/11/16/18/31/33/45/52/58 型九价疫苗（大肠埃希菌）（以 下简称"九价 HPV 疫苗"）"上市许可申请的《受理通知书》。有关详情如下： 一、《受理通知书》的主要信息 九价 HPV 疫苗顺利获批上市，将有利于公司 HPV 疫苗的推广和使用，丰富 公司产品线，进一步增强公司的核心竞争力，为公司持续稳健发展奠定坚实基础。 四、风险提示 1、根据国家关于疫苗注册管理的相关规定，九价 HPV 疫苗上市注册申请获 得受理后，需经过综合审评、生产现场核查等程序，注册申请的最终获批及获 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：603392 证券简称：万泰生物 公告编号：2024-053 北京万泰生物药业股份有限公司 第六届监事会第三次会议决议公告 （3）在提出本意见前，未发现参与2024年半年度报告编制和审议的人员有 违反保密规定的行为。 具体内容详见公司于指定信息披露媒体披露的公司2024年半年度报告全文 及其摘要。 表决结果：同意3票、反对0票、弃权0票。 2、审议通过了《关于公司2024年半年度募集资金存放与实际使用情况的专 项报告的议案》 北京万泰生物药业股份有限公司（以下简称"公司"）于2024年8月12日以电 子邮件方式向全体监事发出第六届监事会第三次会议召开通知和会议材料。本次 会议于2024年8月22日以通讯方式召开。本次会议由公司监事会主席邢庆超先生 主持，应出席监事3人，实际出席监事3人。本次会议的出席人数、召开和表决方 式符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、监事会会议审议情况 1、审议通过了《2024年半年度报告全 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 15%[2]. - The company's revenue for the first half of 2024 was CNY 1,366,045,101.74, a decrease of 67.19% compared to CNY 4,163,641,154.70 in the same period last year[20]. - Net profit attributable to shareholders was CNY 260,480,462.16, down 84.70% from CNY 1,702,358,148.94 year-on-year[20]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 63,520,625.14, a decline of 96.09% compared to CNY 1,623,174,034.86 in the previous year[20]. - Net cash flow from operating activities was CNY 128,547,517.42, a decrease of 22.62% from CNY 166,121,691.21 in the same period last year[20]. - The basic earnings per share decreased by 84.33% to 0.21 CNY compared to the same period last year[21]. - The diluted earnings per share also decreased by 84.33% to 0.21 CNY compared to the same period last year[21]. - The company's net profit for the first half of 2024 was CNY 384,847,977.73, a decrease from CNY 1,482,638,184.97 in the same period of 2023, representing a decline of approximately 74%[177]. - Total operating revenue for the first half of 2024 was CNY 1,366,045,101.74, a decrease of 67.2% compared to CNY 4,163,641,154.70 in the same period of 2023[172]. - Total operating costs for the first half of 2024 were CNY 1,289,398,978.35, down 42.5% from CNY 2,242,973,767.22 in the first half of 2023[172]. Market and User Growth - User data indicates a growth in the active user base by 20% compared to the same period last year, reaching 5 million users[2]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2024, reflecting a growth target of 10%[2]. - Market expansion efforts have led to a 30% increase in sales in international markets, particularly in Southeast Asia[2]. - Strategic partnerships with healthcare providers have been established, aiming to increase market penetration by 15% over the next year[2]. Research and Development - The company is investing RMB 300 million in R&D for new technologies aimed at enhancing diagnostic accuracy and speed[2]. - The company has established a comprehensive vaccine R&D technology platform, including various advanced technologies such as high-throughput expression screening and mRNA vaccine development, supporting its strategic goal to become a leader in the global vaccine industry[59]. - The company is focusing on expanding its market presence in the IVD sector, which is crucial for enhancing diagnostic accuracy and efficiency[26]. - The company has developed a hepatitis C diagnostic test that improves sensitivity by 8-10 times, significantly reducing the window period and transmission risk[34]. - The company has established multiple diagnostic technology platforms, including automated biochemical immunoassay instruments and PCR detection technology, successfully launching various in vitro diagnostic reagent products[50]. Product Development and Innovation - New product launches in the diagnostics segment contributed to a 25% increase in sales volume during the reporting period[2]. - The company has a comprehensive product range in the in vitro diagnostics field, including various testing reagents and automated diagnostic instruments[32]. - The company has achieved significant milestones in HIV diagnostics, including the launch of the world's first urine rapid test for HIV in 2019[33]. - The company has developed a new COVID-19 antigen test with a detection time of 15 minutes, achieving high sensitivity and specificity, and has received certifications from multiple international organizations, exporting to over 40 countries[35]. - The company has launched a new calcitonin product, enhancing its thyroid cancer detection portfolio, which is expected to drive growth in its thyroid function series products[35]. Financial Management and Investments - The company reported a total investment of 504,052.30 million RMB in significant non-equity projects, with an actual investment of 36,124.29 million RMB during the reporting period[91]. - The company has ongoing projects including the expansion of the nine-valent cervical cancer vaccine with a total project amount of 124,918.85 million RMB and actual investment of 10,686.76 million RMB[91]. - The company has a cash management balance of RMB 5.00 billion as of the end of the reporting period, with an authorized limit of RMB 20.00 billion[152]. - The company has a total of 1,298,942,359.86 RMB in other payables, which represents a decrease of 29.20% from the previous period[89]. - The company has received milestone payments totaling approximately 1.34 billion euros (about 1 billion RMB) from GSK for the development of a new cervical cancer vaccine[146]. Corporate Governance and Management Changes - The company appointed Jiang Zhiming as the new General Manager in January 2024, following the resignation of the previous General Manager Qiu Zixin, who will continue as Chairman[104]. - The company held its annual shareholders' meeting on April 19, 2024, to approve the election of the new board and supervisory committee[106]. - The company has undergone significant changes in its board and management structure, with multiple new appointments and resignations[105]. Environmental and Social Responsibility - The company has achieved ISO14001 and ISO50001 certifications, enhancing its environmental management performance[119]. - The company donated HPV vaccines worth 34.8 million yuan during the reporting period as part of its social responsibility initiatives[123]. - The company has implemented online monitoring for wastewater discharge at both facilities, with real-time data uploaded to regulatory platforms[118]. - The company has committed to resource reuse and recycling for large volumes of solid waste generated[120]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[2]. - The company faces financial risks, including potential asset losses from R&D failures and accounts receivable risks due to budget constraints at customer organizations[101]. - The domestic in vitro diagnostic industry is experiencing intense competition, with many companies entering various segments, leading to a trend of product homogenization[98].